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Abstract
Aggregation  of  peptides  and  proteins  into  amyloid  structure  is  one  of  the  most
intensively studied biological phenomena at the moment. To date, there is no devel‐
oped theory that would allow one to determine what kind of mechanism presents in
the given experiment on the basis of aggregation kinetic data. Debates concerning the
mechanism of the amyloid fibrils formation and, in particular, the size of the amyloi‐
dogenic nucleus are still going on. We created such a theory on the basis of the kinetics
of amyloid aggregates formation. In the presented chapter, theoretical and experimen‐
tal  approaches  were  employed for  studding the  process  of  amyloid  formation by
different proteins and peptides. The current kinetic models described in this chapter
adequately describe the key features of amyloid nucleation and growth.
Keywords: amyloidogenic regions, amyloid prediction methods, linear and exponen‐
tial mechanisms of amyloid growth, polymorphism, prion
1. Introduction
Many studies show that the generation of an amyloid fibril is a fundamental property of all
protein molecules, rather than being limited to a narrow range of the so-called amyloid-
forming proteins associated with amyloid diseases,  as was believed until  recently [1,  2].
Normal proteins become toxic upon fibril formation [3]. At the same time, greater cytotoxici‐
ty is characteristic of immature water-soluble fibrils compared to mature insoluble amyloid
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fibrils. It seems that the mechanism of toxicity should be similar to that for fibrils formed by
different proteins. The structure of toxic immature fibrils is certainly rich in β-strands and
should be universal, because specific antibodies against the precursors of amyloid peptide Aβ,
associated with Alzheimer’s disease, recognize the precursors of amyloid fibrils formed by
other proteins with different amino acid sequences [4]. It was demonstrated that samples of
blood serum from patients with Parkinson’s disease show an autoimmune response to insulin
oligomers and fibrils, which should reveal the presence of insulin aggregates in this disease
[5]. Fibril formation depends on the experimental conditions and is expedited by denatur‐
ants: to aggregate, proteins should be unfolded, at least partly [6]. Preliminary unfolding is
not needed for the aggregation of peptides and proteins associated with amyloidosis such as
type II diabetes or Alzheimer’s and Parkinson’s disease, because these proteins are already
unfolded under physiological conditions [7].  However, the majority of natively unfolded
proteins do not aggregate in vivo [8] suggesting that unfolding is necessary, but not suffi‐
cient for the formation of amyloid fibrils. Most likely, there are specific amino acid motifs that
are exposed to the solvent and are more prone to aggregation as compared to other regions of
the amino acid sequence. Experimental findings support the hypothesis that small protein
regions are responsible for the amyloidogenic behavior [9–11].
2. Identification of aggregation sites in proteins responsible for amyloid
formation
We have done comparison of the prediction results for 30 amyloidogenic proteins [12] using
seven methods with experimental data: PASTA2 [13], AmylPred2 [12], Tango [14], MetAmyl
[15], Waltz [16], FoldAmyloid [17], ArchCandy [18]. More detail comparison with full list of
proteins but without new method Archcandy was presented in our recent paper [19]. One can
see that FoldAmyloid (which is a relatively old and simple approach) works better than Waltz
and Archcandy. PASTA2 is a new more sophisticated approach that performs best among the
non-meta-servers. As evident from Table 1, the accuracy and sensitivity of PASTA2 predic‐
Scoring type  PASTA2
90%
specificity 
AmylPred2 Tango MetAmyl
high
specificity 
Waltz best
perfo‐
mance 
FoldAmy‐
loid 
Archcandy
default set‐
tings 
Sensitivity  0.36  0.41  0.19  0.38  0.19  0.28  0.16 
Specificity  0.91  0.86  0.95  0.86  0.94  0.92  0.92 
False regions
predicted as amyloidogen‐
ic 
38  121  37  88  37  31  15 
No. correctly predicted re‐
gions/total 
33/46  42/46  17/46  33/46  22/46  29/46  8/46 
Table 1. Averaged results of amyloid predictions for 30 proteins by various algorithms.
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tions are only smaller better than those of FoldAmyloid. At the same time, comparison of the
overall prediction quality shows only modest improvement, which is due to low sensitivity
partly caused by overprediction and partly by the coarseness of the methods.
3. Possible kinetics schemes for amyloid and prion growth
To explain the kinetic features of the aggregation process of protein molecules, a large number
of schemes were proposed. There are many approaches for describing the kinetics and
mechanism of protein aggregation: kinetic, thermodynamic, and other empirical approaches.
The purpose of the first two was the best approximation of the experimental data and
obtainment of quantitative values of the rate constants describing such processes as nuclea‐
tion, growth, and all other parts of the aggregation process. At present, there is no consen‐
sus whether a protofilament is formed by joining oligomers or by adding monomers. The
following questions can be posed: How many different mechanisms exist in the literature for
describing the protein aggregation? What is the essence of each mechanism? What mecha‐
nisms or models are used in the literature to describe the experimental kinetic curves? What
are the similarities between various mechanisms? The large volume of publications describ‐
ing the formation of amyloid fibrils allows us to reveal two general mechanisms. There are a
mechanism of sequential addition of monomers (linear growth) and a mechanism for
describing the aggregation of prions (exponentional growth). Most of these approaches
somehow go back to the late fifties [20]. In this study, a kinetic scheme for polymerization of
actin was proposed. The experimental data indicated that the polymerization process is very
similar to the condensation reaction: The reaction occurs only when the monomer concentra‐
tion exceeds the critical threshold. The assumption was justified. The cooperative polymeri‐
zation reaction was confirmed by two facts: (1) The reaction rate in the early stages of the
reaction increased upon increasing the concentration of actin; (2) an addition of seed with an
already formed unit led to an immediate transition of all free actin to an aggregate. In 1974,
Hofrichter et al. [21] used the mechanism of sequential monomer addition to the aggregate to
explain the formation of hemoglobin fibrils in sickle cell anemia. To explain the observed effect
of “extreme autocatalysis” and strong concentration dependence, Ferrone with the co-authors
developed a model of “heterogeneous nucleation” [22]. This model assumes the following
sequence of events: First, in the normal course of nucleation, fibrils, and then, subsequent fibrils
may form on its surface. This model is included as an equation for the first stage—the
homogeneous nucleation, and for the second step—heterogeneous nucleation; the equations
were solved numerically. The notion of heterogeneous nucleation was a new and important
contribution to the development of the theory of protein aggregation. In 1983, Frieden and
Goddette [23] used a model of sequential monomer addition to the unit to describe the process
of protein polymerization, with the proviso that each step of monomer addition had its own
reaction rate constant. In 1986, Goldstein and Stryer [24] modified the model of sequential
addition of monomers to the unit to describe the process of protein polymerization. They
identified the nucleus as a “seed” of size s, after the formation of which the kinetic constants
are changed. Using protein amylin, it was shown that nucleation can occur in two ways: fibril-
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independent (or primary nucleation) and fibril-dependent (secondary nucleation) paths. The
contribution of each of these processes depends on the external interfaces (or surfaces). In the
presence of such a surface, the primary nucleation mechanism is dominating; in the absence
of such a surface, the secondary nucleation mechanism is dominating [25]. Heterogeneous
nucleation can be seen from another point of view, as an autocatalytic growth in mature seeds.
It was not shown experimentally whether seeds are formed on the existing surface of the unit,
or the growth simply continues from the surface of the same aggregate. In 1967, Griffith [26]
suggested three possible theoretical mechanisms that could explain the self-replication agent
causing “scrapie” sheep (scrapie). In 1982, Prusiner [27] was able to provide enough experi‐
mental evidence that the “scrapie” infectious agent is the protein called a prion. In 1991,
Prusiner suggested the scheme of transfer and development of prion infection [28]. Based on
the Prusiner’s work, in 1993, Lansbury his work published [29], in which the mechanism of
sequential monomer addition to the seed was applied for analysis of kinetic data.
Figure 1. Alternative scenarios for amyloid growth and corresponding kinetic parameters. T2 is the time of inclusion of
all monomers into the aggregate, Lrel is the ratio between the duration of the lag phase and the time of inclusion of all
monomers into the growing polymer, [M∑] is the total monomer concentration, n* is the size of the primary nucleus,
and n2 is the size of the secondary nucleus. nS is the smallest number of monomers in the stable polymer. Modified
from [33].
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In 2004 in the paper by Collins et al. [30], the formation kinetics of sup35p prion was studied.
It was shown that amyloid aggregate growth occurs upon monomer addition to the fiber ends.
Also the authors performed experiments with agitation and observed catalysis due to fiber
fragmentation, so their kinetic model consisted of three steps: at the first step, oligomers are
formed; at the second step, amyloidal seeds are formed through nucleation-conversion, after
that the autocatalytic growth occurs where autocatalysis takes place because of fragmenta‐
tion. Thus, major schemes of amyloid aggregates formation were drawn. In general, schemes
can be summed up into the following reaction: out of a pool of monomer nuclei (the most
unstable species on the reaction path with the largest free energy) are formed, which then are
somehow converted into seed (the smallest stable amyloid aggregate) which is able to attach
monomers in a way that monomer free energy only decreases, the result of which is that after
some time, all the monomers become associated into fibrils. In some cases, catalysis of reaction
occurs through secondary nucleation or fragmentation. In the presence of a catalyst, the
amyloidal growth regime can be named “exponential,” whereas in the absence of catalysis,
the amyloidal growth can be named linear. It should be mentioned that in this general scheme,
it is not important what one means by the words “monomer protein”—the monomer itself or
some protein aggregate. Despite overall success in the understanding of possible mecha‐
nisms hidden beneath amyloidal aggregation, the relation of the kinetic models to the
experimentally measurable values was still unclear. Thus, the authors of the paper [31] have
shown that despite possible different mechanisms of aggregation, all of the kinetic experi‐
mental data could be successfully approximated by a simple sigmoid curve. Fortunately in the
same year, the careful introspection of the behavior of the logarithm of lag time versus
logarithm of concentration for several amyloidogenic agents by Knowles et al. [32] revealed
that different amyloidogenic agents possess a similar linear dependence in those coordinates
and such dependence is Tlag/Tlag0≈ (C/C0)−1/2, where Tlag0 and C0 are values corresponding to
the smallest concentration. In the paper Dovidchenko et al. [33], the authors studied the
variance in the mechanisms within scheme monomer ->nucleus->fibril growth with/without
catalysis. In the work, the authors were lucky to find bridges between values which can be
calculated directly from experimental data—characteristic times such as lag-time Tlag, time of
inclusion of all monomers into aggregate T2 and relation Lrel = Tlag/T2 and mechanism of
amyloidogenesis. It turned out that through the study of the concentration dependence of
amyloid formation, one can estimate nuclei sizes (the size of the primary nucleus and size of
the secondary nucleus if secondary nucleation takes place) and possible mechanisms. For
example, linear growth (when no catalysis occurs) has a very narrow range of conditions: Lrel
should be independent of the logarithm of concentration and its value should not exceed 0.2.
In the case of exponential mechanism, one should plot a graph of two dependencies: lnT2 versus
ln[MΣ] and Lrel versus ln[MΣ], where MΣ is the initial concentration of monomers. As one can
see from Figure 1, the dependencies should be linear in those coordinates and thus the
calculation of the tangent coefficient of a line drawn through experimental points will point
out what mechanism takes place in the given reaction. However, several tangent coefficients
(for example, −1/2 which can be either the result of a fragmentation mechanism or a bifurca‐
tion mechanism without secondary nucleation) are special cases and can be obtained in
Kinetics of Amyloid Formation by Different Proteins and Peptides: Polymorphism and Sizes of Folding Nuclei of Fibrils
http://dx.doi.org/10.5772/63359
149
different scenarios; for those cases, additional experiments are needed to exclude excess
mechanism variants.
4. Polymorphism of amyloid fibrils
The fully matured fibers are not the most toxic species. The importance of intermediate species
that define the pathway, toxicity, and even the type of fibers formed at the end should be
emphasized. Usually electron microscopy (EM) is used for comprehensive characterization of
the amyloid formation and for control of the amyloid morphology. The probes are collected
for analyzing periodically over duration of all experiments. The main results of EM experi‐
ments at each of the time intervals are the properties of time-dependent structures and their
variability (polymorphism). These analyses usually are performed using both commercial and
recombinant samples. The use of EM in studying the process of amyloid formation is due to
the importance of polymorphism for determining the protein folding pathways. On the other
hand, protein folding pathway depends strongly on its amino acid sequence. Further, the
resulting protein conformation affects the formation of amyloid fibrils, and the same poly‐
peptide sequence may correspond to the fibrils of different morphologies [34]. The fibril
polymorphism is potentially important for the human disease progression, as it may be the
reason for natural variability of amyloid-related pathologies such as amyloidosis of light
chains of immunoglobulins (AL) and the phenomenon of strain variability of prion infection
[34, 35]. The EM images of amyloid fibrils show insignificant morphological differences, and
the fibrils are often represented as twisted or parallel clusters of thin protein filaments. One
should note also that polymorphism is a serious obstacle in studying fibril structures. A
mixture of fibrils of different morphology is always present in solution, and several different
types of fibrils can be seen under the same conditions. This creates a problem for image analyses
because it requires separation of fibrils by their morphology and performing separate analyses
of each type of insulin, Aβ peptide, β2-microglobulin, glucagon, amylin, calcitonin, etc. It is
not completely excluded that different fibril morphologies are due to similar but not identi‐
cal fibril formation pathways. The differences may be formed at the initial steps of fibril
formation including the step of nucleation. The size of the nucleus of a protofibril is still
unknown for almost all proteins and peptides. Nucleation is the limiting step of the amyloid
fibril formation which can start only when the concentration of amyloid proteins exceeds the
critical one. After the nucleation, the fibrils grow rapidly. Proteins may have different sizes of
the protofibril nuclei (see the next sections). Also, the conditions at which the fibrils are formed
may affect its size. This may result in the formation of the fibrils of different morphologies. In
other words, we assume that the fibril formation depends on the nucleation step and goes
through different pathways, thus determining the final fibril morphology. Note also that both
the morphology and molecular structure are sensitive to small differences under conditions
when the fibrils are growing in de novo preparations (under fixed pH, temperature, buffer
composition, and peptide concentration).
Exploring New Findings on Amyloidosis150
4.1. Polymorphism of Aβ fibrils
It was shown previously that peptide Aβ40 forms fibrils of different morphologies even under
the same conditions. For the fibrils formed without mixing, the dominating morphologies are
twisted fibrils, while the activated fibrils will be less twisted yet inclined to form lateral
associations. The inactivated twisted fibrils are the most toxic for the cells [36]. Therefore, it is
important to study all possible formations including oligomers and fibrils, which determine
the natural polymorphism. Moreover, it was shown previously that the fibrils associated with
diseases have the same nucleation center structure called a β-arcade. The β-strands in these
Figure 2. Electron microscopy images of recombinant Aβ40 peptide [0.2 mg/mL, 27 h incubation at 25°C, 50 mM Tris-
HCl (pH 7, 5)]. (a) General view (field) of recombinant Aβ40 peptide after 27 h of incubation. (b–d) Gallery of types of
Aβ40 peptide fibril images at higher magnification: (b) single fibrils; (c) ribbon-like type of fibrils; (d) bundle-like type
of fibrils; (e, f) single fibrils: (e) at horizontal packing; (f) bending sites of the single fibrils. (g) Gallery of ring oligomers.
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structures are parallel to each other. It is interesting to note that this kind of a nucleus structure
is not found in normal proteins and the β-strands are antiparallel to each other [37].
4.1.1. Morphology of recombinant Aβ40 peptides
Figure 2 shows the preparation of recombinant Aβ40 peptide after 27 h incubation at 25°C at
50 mM Tris–HCl (pH 7, 5) and C = 0.2 mg/ml. Polymorphism of generated fibrils is seen. In
addition to single fibrils of several microns in length with a diameter of about 8–9 nm, there
are also fibrils, forming bands of different widths, and bundles. It seems that single fibrils
consist of two filaments. However, under high magnification, it is seen that the fibrils are
formed of rounded ring structures. The matter is that upon staining the preparations, the
staining agent dyes not only their contours, but also flows into different cavities and open‐
ings. This should be taken into account when interpreting EM images; otherwise, a tobacco
mosaic virus fibril would consist of two parallel packed short filaments of 300 nm long. In the
case of the Aβ40 peptide preparation, under high magnification, it is also seen that the staining
agent flows into the openings of ring structures. These ring oligomer structures have a diameter
of about 8–9 nm (the width of a single fibril) and a diameter of the internal opening of about
3 nm. Ring structures or Aβ40 oligomers form single fibrils in such a way, that ring oligom‐
ers are layered on each other. If a fibril is absorbed on the formvar film sideways, we see a
thinner fibril with a diameter of about 4 nm. This size demonstrates an approximate height of
a ring-structured oligomer. As a matter of fact, the height is smaller, because the degree of
Figure 3. Electron microscopy images of Aβ42 peptide from Invitrogen (lot #73269340A). The sample was incubated at
37°C (water). (a) General view of the sample at 97-h incubation. (b, c) Gallery of types of Aβ42 peptide fibrils at higher
magnification: (b) single thin and (c) thick fibrils. (d) Gallery of ring oligomers.
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overlapping of ring-structured oligomers should be taken into account. The greater is the
overlapping, the larger is the height of such packing of fibrils.
4.1.2. Morphology of synthetic Aβ42 peptide (Invitrogen, lot #73269340A)
The EM image of Aβ42 peptide (Invitrogen, lot #73269340A) (Figure 3) shows that after 97 h
of incubation at 37°C (water), fibrils of several microns long are formed. Polymorphism of
fibrils is observed. Thin fibrils with a diameter of about 7–8 nm and more are seen, and more
pronounced polymorphism of the generated fibrils is observed (Figure 3). At the same time,
fibrils of different diameters are present: thin ones of about 7–8 nm and wider fibrils up to
15 nm. Moreover, rounded ring-structured oligomers of about 8 nm in diameter can be seen;
the internal diameter of the ring (the diameter of the hole) is about 3 nm (Figure 3d). At
magnification, it can be seen that an oligomer consists of 4–6 smaller rounded particles
(Figure 3d). It is notable that both thin and thick fibrils are formed of such ring-structured
oligomers. Thin fibrils are characterized by more ordered interaction of separate oligomers,
while thick fibrils are generated due to random sticking of additional oligomers along the fibril
axis. Because of this way of generation, fibrils look uneven in EM images with a tendency to
branching [38].
Thus, using the EM method, we have demonstrated that fibrils of these peptides are formed
by association of rounded ring structures. Negatively stained TEM images of fibrils extract‐
ed from AD brain tissues [39] are very similar to our EM results. Moreover, similar struc‐
tures are observed elsewhere [40].
4.2. Polymorphism of insulin fibrils
Insulin has a high tendency to aggregation and forms fibrils. Insulin fibrils were first descri‐
bed in 1940 by Waugh [41]. At present, the conditions leading to the formation of active insulin
fibrils are known [42]. Insulin fibrillation occurs upon various environmental changes (pH,
ionic conditions, temperature, organic solvents, and agitation); it also depends on the methods
for producing insulin, its delivery, and storage. It should be noted that the human insulin
fibrillation is slower than that of the best studied bovine insulin [42–47].
Currently, all insulin preparations for therapeutic purposes are prepared in the form of a Zn-
containing hexamer, since in this condition it is more stable and resistant to the formation of
fibrils. When treating diabetes, insulin penetrates into muscles by injection, where it typical‐
ly forms deposits. The large size of the insulin hexamer slows its adsorption, because the
hexamer must go through the dimers in the monomeric state and only in this way penetrate
into the bloodstream. This leads to slowing down the interaction with insulin receptors and
the need to take insulin 1–1.5 h before mealtime.
Despite intensive studies of fibrillogenesis of insulin, there is no generally accepted scheme
for the formation of mature fibrils. The main difficulties arise in interpreting the beginning of
the fibrillation process. Polymerization of insulin begins from the transition of the monomer
protein from the native state to the partially unfolded conformation which can be amyloido‐
genic. The strong dependence of the reaction of polymerization on various external parame‐
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ters leads to the formation of insulin fibrils with different morphology, which complicates the
analysis of the general scheme of fibril formation.
For electron microscopy (EM) investigations, insulin samples were used at a concentration
of 0.2 mg/ml. Zinc-free recombinant human insulin was obtained from “Gerofarm-Bio”
(Obolensk, Russia) and was checked by the tandem mass spectrometry technique (LCQ Deca
XP, Thermo Finnigan, USA). According to the EM data on polymerization of human insulin,
the mature protein fibrils appeared only after 8 h of insulin incubation. Active polymeriza‐
tion of insulin occurs up to 10–11 h of incubation. This is accompanied by the elongation of
the fibrils for both samples up to 10–12 μm. The fibrils interact laterally with each other,
resulting in the formation of big clusters composed from ribbons, bundles, and twisting
bundles (Figure 4). Protein aggregation is the result of increasing the incubation time up to
24 h. According to the EM data, the number of large fibril clusters increases in the samples
after 24 h, but the length of the fibrils does not change (remains about 10–12 μm) [48].
Figure 4. Electron microscopy images of human zinc-free recombinant insulin (0.2 mg/ml, 24 h incubation at 37°C, 20%
acetic acid (pH 2.0), 140 mM NaCl). (a) General view (field) of human insulin after 24 h of incubation. (b–d) Gallery of
images of types of insulin fibrils at higher magnification: (b) single fibrils; (c) ribbon-like type of fibrils; (d) bundle-type
of fibrils. (e, f) The thinnest fibrils: (e) at horizontal packing; (f) at vertical packing of ring oligomers.
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5. Example of amyloid growth by the linear nucleation-elongation
mechanism (actin, apolipoprotein C-II)
Most quantitative models for linear polymerization stem from the work performed more than
half a century ago [20] proposing a kinetic model for actin polymerization. Only two of the
proteins (apolipoprotein C-II [49]: Lrel < 0.1 with the primary nucleus size n* ≈ 4–5 and actin
with n* ≈ 3), studied in our analysis, exhibit linear growth. Formation of actin filaments occurs
by linear growth—fibrils increase only due to attachment of monomers to the aggregate ends.
This is supported by literature data [50] and by analysis of kinetic data (Figure 1). According
to the theory advanced in [33] for linear growth (observed in actin), the characteristic time of
the relative lag-period Lrel does not exceed 0.2 and is independent of ln[MΣ] as in the case of
actin (Figure 5) [50]. The size of the primary nucleus was calculated from the slope to be
n = 3.46 ± 0.28.
Figure 5. (a) Dependence of normalized ThT fluorescence on time for actin [50]. (b) Dependence of Lrel on lnT2. (c)
Dependence of Lrel on ln[MΣ]. The slope angle of the fitted line is about −0.01, that is, Lrel is independent of ln[MΣ]. All
Lrel values are also <0.2 which, according to the models of formation of fibrillar aggregates, means that the formation of
actin fibrils proceeds by the linear mechanism (see [33]). The errors are computed with the Student’s coefficients corre‐
sponding to 0.95 confidence level.
6. Examples of amyloid growth by the exponential mechanism and sizes of
folding nuclei of fibrils formed by different agents
In order to estimate the size of fibril nucleus (the most unstable state on the monomer to the
fibril pathway) and a possible scenario for the formation of aggregates, it is necessary to make
a number of kinetic experiments, where the only variable parameter is the monomer concen‐
tration. Characteristic times Tlag (the lag-period duration), T2 (the time of transition of all
monomers into an aggregate), and Lrel (the Tlag/T2 ratio) are calculated for each experimental
curve. It was demonstrated that the dependences of lnT2 and Lrel on ln[MΣ] (the logarithm of
the initial concentration of monomers) are linear, with gradients that can be used for the
computation of fibril nucleus sizes (including those of non-amyloid type) and for elucida‐
tion of the mechanism of aggregate formation.
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If Lrel > 0.2, the linear growth model is excluded, and, independently of lnT2 and Lrel depend‐
ence on ln[MΣ], only the exponential growth scenario remains. The dependences of lnT2 on
ln[MΣ] and Lrel on ln[MΣ] are formally different for different exponential scenarios (i.e.,
“growth from the surface,” “fragmentation,” and “bifurcation”). However, it is impossible, for
example, to distinguish the bifurcation from the fragmentation scenario from the kinetics alone
if the size n2 of the secondary nucleus of bifurcation is zero; this implies the need for direct
observations of fibril shapes to distinguish these cases (see Refs. [33, 48] for more details).
6.1. Insulin
Now we can present three general schemes of insulin amyloid formation, which differ by the
size of folding nuclei of fibrils. For the first type, the size of nucleus is one monomer [44, 51–
53]. For the second scheme of fibril formation, the size of nucleus is two monomers and the
dimers are precursors of fibrils [5, 54, 55]. For the third scheme of polymerization, oligomers
are precursors of fibrils, and the size of oligomer can vary from three to six monomers [42, 43,
56–58].
The basis for choosing between different mechanisms of formation of fibrils is to detect various
soluble oligomers. However, at low concentrations and at early times, it is difficult to
accomplish accurate detection of the initial aggregates. For this purpose, a variety of optical
methods, as well as Cryo-transmission-EM, atom force microscopy, and small-angle X-ray
scattering are used [55, 57–59]. However, all these methods are not quantitative, have no
reliable standards, do not provide the full size distribution, may yield abnormal results
(with microscopic approaches—interaction with the surface during adsorption of samples),
and require the analysis of the results of certain programs to prove the statistical signifi‐
cance [52]. Although all these methods provide valuable information, none of them can
convincingly demonstrate how an unstable nucleus grows to a stable seed for further growth
of protofibrils, and many experimental and theoretical models are based on this assumption.
Figure 6. (a) Dependence of normalized ThT fluorescence on time for insulin [48]. The approximation line calculated
for insulin amyloid formation with the experimental data from (a) by the least-squares method plotted in coordinates
(b): {lnT2, ln[MΣ]} and (c): {Lrel, ln[MΣ]}; [MΣ] is in mg/ml, T2 in min. The tangent coefficients of the approximation lines
are −0.51 ± 0.13 for d(lnT2)/d(ln[MΣ]) and 0.15 ± 0.31 for d(Lrel)/d(ln[MΣ]); the errors are computed with the Student’s
coefficients corresponding to 0.95 confidence level.
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The growth of amyloid fibrils was studied by thioflavin T (ThT) fluorescence, which drasti‐
cally increases when ThT is bound to fibrils (Figure 6a). The renormalized curves, presented
in Figure 6a, are very similar to one another. They have large lag periods, thus excluding the
linear growth scenario. The obtained analytical solution and computer modeling allowed us
to determine the size of the nucleus from the experimentally obtained concentration depend‐
ences of the relationship between the lag-time duration and the time of growth of amyloid
fibrils [33]. Figure 6b, c illustrates determination of the fibrillation scenario and the nuclei
sizes (n*, n2) for human insulin (see Table 2) [48]. The value d(lnT2)/d(ln[MΣ]) ≈ −0.5 is
inconsistent with the “growth from the surface” model but consistent with “linear growth”
(which, though, should have Lrel < 0.2, which is inconsistent with Lrel), “fragmentation” (which,
though, is inconsistent with EM images shown in Figure 4), and “bifurcation” (consistent with
the EM images), with the secondary nucleus size n2 = 0 calculated as −1 − d(lnT2)/d(ln[MΣ]); the
primary nucleus size n* = 1 + n2 − d(Lrel)/d(ln[MΣ]) = 1 (see Table 2). According to the elaborat‐
ed theory, it means that the size of the primary nucleus corresponds to one monomer.
Amyloid-forming
protein or peptide and a
ref. to its experimental
study
[MΣ],
mg/ml
(min–max) 
ln(T2/min) at
various [MΣ]
(min–max) 
Lrel at
various
[MΣ]
(min–max) 
n* ± Δn*,
primary
nucleus
n2 ± Δn2,
secondary
nucleus
Model that follows
from the Lrel and lnT2
on [MΣ]
dependencies
Human insulin [48]
(37°C)
2.0–15 4.71–5.70 1.78–2.48 0.86 ± 0.44 0.01 ± 0.13 Exponential
Human insulin [65]
(45°C)
2.5–20 3.60–4.18 5.17–5.56 1.13 ± 0.19 −0.48 ± 0.16 Exponential
LysPro human insulin
[48] (37°C)
2.0–15 5.78–4.81 2.04–4.38 0.63 ± 1.04 −0.29 ± 0.24 Exponential
Figure 7. (a) Dependence of normalized ThT fluorescence on time for LysPro insulin [48] The approximation line calcu‐
lated for LysPro insulin amyloid formation with experimental data from (a) by the least-squares method plotted in co‐
ordinates (b): {lnT2, ln[MΣ]} and (c): {Lrel, ln[MΣ]}; [MΣ] is in mg/ml, T2 in min. The tangent coefficients of the
approximation lines are −0.35 ± 0.25 for d(lnT2)/d(ln[MΣ]) and 0.07 ± 0. 80 for d(Lrel)/d(ln[MΣ]); the errors are computed
with the Student’s coefficients corresponding to 0.95 confidence level.
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Table 2. The range of Lrel and lnT2 values, the sizes of the primary (n*) and secondary (n2) nuclei and the amyloid
growth scenarios obtained from experimental kinetic data alone.
6.2. LysPro human analog insulin
We have investigated the kinetics of formation of fibrils by monomeric rapid-acting insulin
LysPro [48]. According to our data, fibril formation of the insulin analog at pH 2 proceeds
by 5 h longer than that of the recombinant human insulin. These data seem to us important
because the rate of aggregation of insulin preparations is an important health problem not only
in the production and storage of insulin, but also for its frequent injections. In this regard, the
process of fibrillation should be analyzed for all developed analogs, already prepared for
clinical trials and for mass production. Examination of EM images of growing insulin LysPro
fibrils shows that they occurred with a kind of the “bifurcation plus lateral growth” scenario
[48]. The growth of amyloid fibrils was studied (Figure 7) by thioflavin T (ThT) fluorescence,
which drastically increases when ThT is bound to fibrils. The dependence of Lrel and lnT2 on
ln[MΣ] (Figure 7) was used to estimate sizes of the primary and secondary nuclei. Similar to
insulin fibrils, the size of the first nucleus is one monomer, and the size of the secondary nucleus
is zero (see Table 2). It should be noted that “one monomer” may correspond to the oligom‐
er structure consisting of 2–6 monomers, if we did not start from the pure monomers in
solution.
6.3. Aβ40
The experimental kinetics data on the formation of amyloid aggregates, which we used to
calculate the sizes of nuclei of amyloid protofibrils formed by Aβ40, were taken from paper
[60]. For all the experimental data, we obtained Lrel >> 0.2, which means that the process goes
by the exponential mechanism of fibril formation (Figure 8). For Aβ40, we obtained that the
size of the primary nucleus is two monomers, and the secondary nucleus size is one monomer.
Figure 8. (a) Dependence of normalized ThT fluorescence on time for Aβ40 [60]. The approximation [Insert figure cap‐
tion here] line calculated for Aβ40 amyloid formation with experimental data from (a) by the least-squares method
plotted in coordinates (b): {lnT2, ln[MΣ]} and (c): {Lrel, ln[MΣ]}; [MΣ] is in μM, T2 in hours. The tangent coefficients of the
approximation lines are −0.79 ± 0.18 for d(lnT2)/d(ln[MΣ]) and −0.03 ± 0.32 for d(Lrel)/d(ln[MΣ]); the errors are computed
with the Student’s coefficients corresponding to 0.95 confidence level.
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6.4. Aβ42
The exponential growth with branching takes place for both Aβ40 and Aβ42 peptides (see
Figures 8 and 9). Interestingly, according to our analysis, for Aβ42, the size of the primary
nucleus of the amyloid protofibril is larger than that of Aβ40, although the mechanism of
amyloid fibril formation must be similar. This is consistent with the recent data, which
compares the behavior of the two peptides during the aggregation process [60]. The primary
nucleus size for Aβ42 is three monomers, and the secondary nucleus size is two monomers.
Figure 9. (a) Dependence of normalized ThT fluorescence on time for Aβ42 [61]. The approximation line calculated for
Aβ42 amyloid formation with experimental data from (a) by the least-squares method plotted in coordinates (b): {lnT2,
ln[MΣ]} and (c): {Lrel, ln[MΣ]}; [MΣ] is in μM, T2 in hours. The tangent coefficients of the approximation lines are
−1.48 ± 0.14 for d(lnT2)/d(ln[MΣ]) and 0.22 ± 0.13 for d(Lrel)/d(ln[MΣ]); the errors are computed with the Student’s coeffi‐
cients corresponding to 0.95 confidence level.
6.5. Human cardiac titin immunoglobulin domain I27 (TI27)
To determine the sizes of folding nuclei for amyloid formation, calculations were done using
the data of aggregation kinetics for the I27 immunoglobulin domain from human cardiac
titin (TI27) [62]. The set of data was digitized, and in the case of TI27, part of the curve was
excluded from the analysis. It was found that the growth of amyloids formed by TI27 is
exponential, that is, in addition to the primary core nucleation secondary nucleation by a
branching mechanism also takes place, accelerating the formation of new fibrils.
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Figure 10. (a) Dependence of normalized ThT fluorescence on time for TI27 [62]. (b) Dependence of lnT2 on ln[MΣ] for
TI27. This was used to calculate the size of the secondary nucleus. The slope of the fitted line is about −1.26 which,
according to formulas from [33], indicates that the size of the secondary nucleus is n2 = 1.52 ± 0.36. (c) Dependence of
Lrel on ln[MΣ] for TI27. The slope of the fitted line is −0.1, that is, Lrel is dependent on ln[MΣ]. Some Lrel values exceed 0.2
and, according to [33], cannot be explained by the linear model. The size of the primary nucleus was calculated based
on the size of the secondary nucleus, and the slope of the straight line is 2.42 ± 0.46. The errors are computed with the
Student’s coefficients corresponding to 0.95 confidence level.
It is seen from Figure 10c that though the values of Lrel for TI27 do not exceed 0.2, Lrel de‐
pends on ln[MΣ] and so, as mentioned above, cannot occur by the linear mechanism. This effect
can be explained by the presence of second nucleation cores with n2 = 1.52 ± 0.36 (Figure 10b).
It is interesting that in spite of the difference in the aggregation mechanism, the size of the
primary nucleation core for TI27 was 2.42 ± 0.46 (Figure 10c) similar (within error) to the
primary nucleation core, 3.46 ± 0.28 (Figure 5), calculated for actin [50].
7. Concluding remarks
Amyloid fibril polymorphism suggests various ways of their formation from monomers
through different oligomers (intermediates of various sizes and shapes) to mature fibrils of
different morphology. It is very likely that the surface of the formed fibrils can serve as a matrix
for lateral polymerization of monomers/oligomers on it, as reported in the literature [47, 63,
64]. The above complicates the explanation of the mechanism of formation of fibrils and the
proposal of a single scheme of polymerization for many proteins. It should be noted that a
combination of several mechanisms is quite possible and can be observed sometimes in
experiments.
Thus, despite some common features of formation of fibrils of different proteins, each of them
has its own specific route for fibrillogenesis, which is originally determined by the amino acid
sequence of the protein and is strongly dependent on environmental conditions and seed
addition. It is clear that there is need for a serious analysis of data on various proteins to explain
various routes for fibril formation that will help identify conditions that affect the initial
formation paths (lag time) and find ways to block the entire process, which is an important
task in the prevention and treatment of diseases associated with amyloid deposits.
A detailed study of molecular and cellular processes underlying the development of protein‐
opathy, search for targets for drug development and the use of the obtained data in the
development of methods for early diagnosis are essential for the successful treatment and
prevention of common diseases. Due to the new generation of neuroprotective drugs acting
directly on the pathogenesis of the disease, all components of the cascade of pathological key
protein aggregation proteinopathy can be regarded as potential targets. We believe that the
combination of theoretical and experimental approaches employed throughout our research
is particularly useful and productive for obtaining new important results.
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